AstraZeneca-Funded Non-Clinical PhD Studentship: Defining and targeting immune-regulatory metabolic niches during benign-to-malignant transformation of pancreatic cancer

This AstraZeneca-Funded Non-Clinical PhD Studentship covers an index-linked student stipend for 4 years, tuition fees (at Home rate only) and an allocation towards project consumables and training. The successful student will become part of a cohort of Cambridge-AstraZeneca students who will spend time at both institutions over the course of their PhD and come together as a group for training and social events. The student will be working on a collaborative project entitled 'Defining and targeting immune-regulatory metabolic niches during benign-to-malignant transformation of pancreatic cancer' jointly supervised by Dr Tim Halim at the CRUK Cambridge Institute, Dr Albert Koulman at the Institute of Metabolic Science, and Dr Gregory Hamm at AstraZeneca. The studentship is designed for candidates with excellent laboratory skills and a strong background in immunology, molecular biology, computational biology and image analysis. The successful candidate is expected to have excellent communication, organisational and time-management skills, creative and rational problem solving, and be highly motivated to drive an independent research project.